Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rezolute, Inc. - Common Stock (NV) (NQ:RZLT)

4.525 +0.215 (+4.99%)
Streaming Delayed Price Updated: 1:14 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rezolute, Inc. - Common Stock (NV)

< Previous 1 2 Next >
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Inc. (NASDAQ: RZLT) Climbs to New 52-Week High
Via Investor Brand Network
Rezolute, Inc. Announces Closing of Underwritten Offering
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Rezolute, Inc.
Via GlobeNewswire
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit demonstrated in Expanded Access Program 
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025 
From Rezolute, Inc.
Via GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Additional $6.7M in funding resulting in approximately $67M in gross proceeds 
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Rezolute, Inc.
Via GlobeNewswire
Rezolute to Participate in the Jefferies Global Healthcare Conference
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
From Rezolute, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.